| Jun 14 |
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
|
| Jun 10 |
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
|
| Jun 6 |
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
|
| Jun 5 |
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
|
| May 29 |
Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
|
